Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales ...

Amgen Inc (NASDAQ:AMGN) shares were slightly lower in premarket trading despite posting better-than-expected quarterly profit ...

Non-GAAP earnings per share for Q2 2025 beat estimates by 14.0%, rising to $6.02 (non-GAAP) and up 21% year over year (non-GAAP). Revenue increased 9% to $9.2 billion, exceeding analyst expectations ...

Biotech company Amgen (NASDAQ:AMGN) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 9.4 ...

Fifteen of the biotechnology company's products delivered at least double-digit sales growth in the second quarter including Repatha, Evenity and Imdelltra. The media giant will take ownership of the ...

Amgen Inc (NASDAQ:AMGN) saw a modest decline in premarket trading even after reporting quarterly profit and revenue results ...

Analysts expect Gilead Sciences to report an earnings per share (EPS) of $1.95. Investors in Gilead Sciences are eagerly ...

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.

Amgen beat Q2 earnings and revenue expectations, raised 2025 guidance, and reported strong product sales growth across key ...

Explore Amgen's Q2 2025 earnings insights, showcasing 9% revenue growth, robust product performance, and innovation in obesity, rare disease, and ...

Novo claims the defendants are steering patients toward compounded semaglutide that has not been approved by regulators; in ...

U.S. health regulators are warning doctors and patients about safety issues with two separate Boston Scientific heart devices ...